Abingdon Health inks manufacturing agreement for BioSure Covid tests

(Alliance News) - Rapid test developer and manufacturer Abingdon Health PLC on Friday said it has ...

Alliance News 23 July, 2021 | 9:08AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Rapid test developer and manufacturer Abingdon Health PLC on Friday said it has signed an exclusive manufacturing agreement with BioSure Ltd.

Shares in Abingdon Health were up 7.1% at 43.39 pence each in London on Friday morning.

BioSure is a Nazeing, Essex-based company specialising in the provision of rapid in-vitro diagnostic testing solutions.

Under the terms of the exclusive agreement, Abingdon will manufacture BioSure's own lateral flow tests in the field of Covid-19. The contract manufacturing services will utilise lateral flow manufacturing facilities at Abingdon's York and Doncaster sites.

"We are delighted to be supporting BioSure and building on our long-term collaboration with the BioSure team. We are committed to supporting the deployment of these much needed lateral flow test to the UK and international markets," said Abingdon Health Chief Executive Chris Yates.

By Amrit Sahota; newsroom@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Abingdon Health PLC 12.00 GBX -2.04 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures